REVIEW ARTICLESCariprazine specificity profile in the treatment of acute schizophrenia a meta-analysis and meta-regression of randomized-controlled trialsCorponi, Filippoa; Serretti, Alessandroa; Montgomery, Stuartb; Fabbri, Chiaraa Author Information aDepartment of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy blmperial College School of Medicine, London, UK Correspondence to Alessandro Serretti, MD, PhD, Department of Biomedical and Neuromotor Sciences, University of Bologna, Viale Carlo Pepoli 5, 40123 Bologna, Italy Tel:+39 051 658 4233; fax:+39 051 521 030; e-mail: [email protected] Received March 23, 2017 Accepted July 3, 2017 International Clinical Psychopharmacology: November 2017 - Volume 32 - Issue 6 - p 309-318 doi: 10.1097/YIC.0000000000000189 Buy SDC Metrics Abstract Cariprazine is a new dopamine D2 and D3 receptor partial agonist antipsychotic. Meta-analytic evidence of efficacy in acute schizophrenia and specific groups of patients is lacking. We carried out a meta-analysis in patients with acute schizophrenia to evaluate the efficacy of cariprazine over placebo and active comparators in overall symptoms, positive and negative symptoms and quality of life. Low and high (≥6 mg/day) doses were tested separately. The possible effect of clinical-demographic modulators was also tested. Four studies (2144 patients) were included. Both high and low cariprazine doses proved superior to placebo in all symptom domains. The standardized mean difference (SMD) to placebo showed a modest impact on overall symptoms compared with meta-analytic results for other antipsychotics (SMD was similar to lurasidone, asenapine, ziprasidone and aripiprazole, but lower than risperidone, quetiapine and olanzapine). The SMD to placebo on negative symptoms was superior to many antipsychotics including aripiprazole, with a slightly more relevant effect of cariprazine low doses. This effect was probably on secondary negative symptoms since the short-term follow-up of the studies included. Meta-regression data further refined the compound clinical profile, suggesting that cariprazine may be particularly useful in young patients with a relatively short duration of disease. Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.